Neuphoria Therapeutics Denounces Lynx1's Misleading Statements, Urges Stockholders to Vote for its Nominees.

lunes, 1 de diciembre de 2025, 8:08 am ET1 min de lectura
NEUP--

Neuphoria Therapeutics is addressing what it believes is a deceptive campaign by Lynx1 Master Fund LP to deflect attention from its own shortcomings. The company urges stockholders to trust its commitment to transparency and value creation by voting FOR its nominees Peter Miles Davies and David Wilson and AGAINST Lynx1's nominees. Neuphoria believes Lynx1's assertions are false and misleading.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios